Literature DB >> 10666240

Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins.

L M Schang1, A Rosenberg, P A Schaffer.   

Abstract

We have previously shown that two inhibitors specific for cellular cyclin-dependent kinases (cdks), Roscovitine (Rosco) and Olomoucine (Olo), block the replication of herpes simplex virus (HSV). Based on these results, we demonstrated that HSV replication requires cellular cdks that are sensitive to these drugs (L. M. Schang, J. Phillips, and P. A. Schaffer. J. Virol. 72:5626-5637, 1998). We further established that at least two distinct steps in the viral replication cycle require cdks: transcription of immediate-early (IE) genes and transcription of early (E) genes (L. M. Schang, A. Rosenberg, and P. A. Schaffer, J. Virol. 73:2161-2172, 1999). Since Rosco inhibits HSV replication efficiently even when added to infected cells at 6 h postinfection, we postulated that cdks may also be required for viral functions that occur after E gene expression. In the study presented herein, we tested this hypothesis directly by measuring the efficiency of viral replication, viral DNA synthesis, and expression of several viral genes during infections in which Rosco was added after E proteins had already been synthesized. Rosco inhibited HSV replication, and specifically viral DNA synthesis, when the drug was added at the time of release from a 12-h phosphonoacetic acid (PAA)-induced block in viral DNA synthesis. Inhibition of DNA synthesis was not a consequence of inhibition of expression of IE or E genes in that Rosco had no effect on steady-state levels of two E transcripts under the same conditions in which it inhibited viral DNA synthesis. Moreover, viral DNA synthesis was inhibited by Rosco even in the absence of protein synthesis. In a second series of experiments, the replication of four HSV mutants harboring temperature-sensitive mutations in genes essential for viral DNA replication was inhibited when Rosco was added at the time of shift-down from the nonpermissive to the permissive temperature. Viral DNA synthesis was inhibited by Rosco under these conditions, whereas expression of viral E genes was not affected. We conclude that cellular Rosco-sensitive cdks are required for replication of viral DNA in the presence of viral E proteins. This requirement may indicate that HSV DNA synthesis is functionally linked to transcription, which requires cdks, or that both viral transcription and DNA replication, independently, require viral or cellular factors activated by Rosco-sensitive cdks.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10666240      PMCID: PMC111691          DOI: 10.1128/jvi.74.5.2107-2120.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  82 in total

1.  Temperature-sensitive mutants of herpes simplex virus type 1 defective in transcriptional and post-transcriptional functions required for viral DNA synthesis.

Authors:  D S Parris; R J Courtney; P A Schaffer
Journal:  Virology       Date:  1978-10-15       Impact factor: 3.616

2.  A cellular function can enhance gene expression and plating efficiency of a mutant defective in the gene for ICP0, a transactivating protein of herpes simplex virus type 1.

Authors:  W Cai; P A Schaffer
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

3.  VP16 targets an amino-terminal domain of HCF involved in cell cycle progression.

Authors:  A C Wilson; R N Freiman; H Goto; T Nishimoto; W Herr
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

4.  Control of mRNA stability by the virion host shutoff function of herpes simplex virus.

Authors:  A A Oroskar; G S Read
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

5.  Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication.

Authors:  W A Bresnahan; I Boldogh; P Chi; E A Thompson; T Albrecht
Journal:  Virology       Date:  1997-05-12       Impact factor: 3.616

6.  Analysis of cyclin-dependent kinase activity after herpes simplex virus type 2 infection.

Authors:  A Hossain; T Holt; J Ciacci-Zanella; C Jones
Journal:  J Gen Virol       Date:  1997-12       Impact factor: 3.891

7.  Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant.

Authors:  D J Goldstein; S K Weller
Journal:  Virology       Date:  1988-09       Impact factor: 3.616

8.  Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription.

Authors:  L M Schang; J Phillips; P A Schaffer
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Phosphorylation of E2F-1 by cyclin A-cdk2.

Authors:  M Kitagawa; H Higashi; I Suzuki-Takahashi; K Segawa; S K Hanks; Y Taya; S Nishimura; A Okuyama
Journal:  Oncogene       Date:  1995-01-19       Impact factor: 9.867

10.  Cyclin A is required at two points in the human cell cycle.

Authors:  M Pagano; R Pepperkok; F Verde; W Ansorge; G Draetta
Journal:  EMBO J       Date:  1992-03       Impact factor: 11.598

View more
  43 in total

1.  Posttranslational processing of infected cell proteins 0 and 4 of herpes simplex virus 1 is sequential and reflects the subcellular compartment in which the proteins localize.

Authors:  S J Advani; R Hagglund; R R Weichselbaum; B Roizman
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

2.  E2F proteins are posttranslationally modified concomitantly with a reduction in nuclear binding activity in cells infected with herpes simplex virus 1.

Authors:  S J Advani; R R Weichselbaum; B Roizman
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Explant-induced reactivation of herpes simplex virus occurs in neurons expressing nuclear cdk2 and cdk4.

Authors:  Luis M Schang; Andrew Bantly; Priscilla A Schaffer
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

4.  Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication.

Authors:  Ayumi Kudoh; Tohru Daikoku; Yutaka Sugaya; Hiroki Isomura; Masatoshi Fujita; Tohru Kiyono; Yukihiro Nishiyama; Tatsuya Tsurumi
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

5.  Inhibition of HTLV-1 transcription by cyclin dependent kinase inhibitors.

Authors:  Lai Wang; Longwen Deng; Kaili Wu; Cynthia de la Fuente; Dai Wang; Kylene Kehn; Anil Maddukuri; Shanese Baylor; Francisco Santiago; Emmanuel Agbottah; Sylviane Trigon; Michel Morange; Renaud Mahieux; Fatah Kashanchi
Journal:  Mol Cell Biochem       Date:  2002-08       Impact factor: 3.396

6.  Pocket protein p130/Rb2 is required for efficient herpes simplex virus type 1 gene expression and viral replication.

Authors:  G L Ehmann; H A Burnett; S L Bachenheimer
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

7.  Herpes Simplex Virus 1 ICP22 Suppresses CD80 Expression by Murine Dendritic Cells.

Authors:  Harry Matundan; Homayon Ghiasi
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

8.  Cyclin-dependent kinase activity is required for efficient expression and posttranslational modification of human cytomegalovirus proteins and for production of extracellular particles.

Authors:  Veronica Sanchez; Deborah H Spector
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

9.  Inhibition of cyclin-dependent kinase 1 by purines and pyrrolo[2,3-d]pyrimidines does not correlate with antiviral activity.

Authors:  David L Evers; Julie M Breitenbach; Katherine Z Borysko; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  Classic swine fever virus NS2 protein leads to the induction of cell cycle arrest at S-phase and endoplasmic reticulum stress.

Authors:  Qing-hai Tang; Yan-ming Zhang; Li Fan; Gang Tong; Lei He; Chen Dai
Journal:  Virol J       Date:  2010-01-11       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.